![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Pharmacology, University of Oslo, Oslo, Norway
Human 5-hydroxytryptamine7 (5-HT7) receptors display characteristics shared with receptors believed to form a tight physical coupling with G protein in the absence of ligand. Some receptors apparently preassociated with Gi/o and Gq/11 are reported to inhibit the signaling of other similarly coupled G protein-coupled receptors by limiting their access to activate a common G protein pool. Therefore, we determined whether 5-HT7 receptor expression was sufficient to limit signaling of endogenously expressed Gs-coupled receptors in human embryonic kidney (HEK) 293 cells. Using the ecdysone-inducible expression system, which allows for the titration of increasing receptor density in the same clonal cell line, we compared the effects of 5-HT4(b) and 5-HT7(a,b,d) receptor expression on adenylyl cyclase (AC) stimulation by the endogenous Gs-coupled
-adrenergic (
AR) and prostanoid EP (EPR) receptors.
AR- and EPR-stimulated AC activity was attenuated by 5-HT7 receptor expression in both membrane preparations and intact HEK293 cells.
AR- and EPR-stimulated AC activity was unaffected by expression of the Gs-coupled 5-HT4 receptor. The mechanism of this heterologous desensitization seems independent of protein kinase A activation, nor does it occur at the level of G protein activation because 1)
AR- and EPR-stimulated AC activity was not restored to control values when G
s was overexpressed; and 2)
1AR and
2AR activation of G
s was unaffected by the expression of 5-HT7 receptors. In addition, overexpression of AC isoforms was unable to rescue
AR- and EPR-stimulated AC activity. Therefore, 5-HT7 receptors probably limit access and/or impede activation of AC by
AR and EP receptors. Although the 5-HT7 receptor may preassociate with G protein and/or AC, the mechanism of this heterologous desensitization remains elusive.
Address correspondence to: Dr. Finn Olav Levy, Department of Pharmacology, University of Oslo, P.O. Box 1057 Blindern, N-0316 Oslo, Norway. E-mail: f.o.levy{at}medisin.uio.no